The legal action, filed in the U.S. District Court for the District of Connecticut under the name Basma v. GeneDx Holdings Corp., accuses the genomics firm and its top executives of violating the Securities Exchange Act of 1934. The suit centers on the company’s 2025 acquisition of Fabric Genomics, an AI-focused interpretation firm. Plaintiffs allege that GeneDx issued misleading statements that concealed significant operational and viability issues within the acquired entity.
In section Releases
GeneDx Investors Face August Deadline for Class Action Lawsuit
A 49% single-day stock collapse has triggered a federal class action lawsuit against GeneDx Holdings Corp. Investors who purchased the company’s common stock between April 16, 2025, and May 4, 2026, now have until August 3, 2026, to apply for lead plaintiff status in the ongoing litigation.
The fallout became public on May 4, 2026, when GeneDx reported its first-quarter results. The disclosure revealed a sharp decline in adjusted gross margins—dropping from 74% to 69%—and a $31.3 million impairment loss linked directly to Fabric Genomics. Consequently, the firm slashed its projected annual earnings from a range of $540-$555 million down to $475-$490 million. The law firm Robbins Geller Rudman & Dowd LLP is currently representing the class, inviting shareholders who sustained substantial losses to participate in the lead plaintiff process before the August deadline.
Comments (0)
No comments yet. Be the first!